A review of current anti-HCV treatment regimens and possible future strategies

Bibliography

• Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:41-6
   PubMedGoogle Scholar
• Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004;24(Suppl 2):3-8
   PubMed Web of Science ®Google Scholar
• Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001;33:321-7
   PubMed Web of Science ®Google Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002;36:S3-20
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007;131:702-07
   PubMed Web of Science ®Google Scholar
• Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004;63:171-80
   Google Scholar
• Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19
   PubMed Web of Science ®Google Scholar
• Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998;143:2493-2503
   PubMed Web of Science ®Google Scholar
• Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006;45:204-13
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-79
   PubMed Web of Science ®Google Scholar
• Weiland O, Hollander A, Mattsson L, et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008;15:641-5
   PubMed Web of Science ®Google Scholar
• Chronic Hepatitis C: Current Disease Management. NIH Public Health Advisory. Bethesda, MD: National Institutes of Health, 2006. Available from: www.health.nih.gov/topic/HepatitisC
   Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Lawitz M, Shiffman ML, et al. Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. J Hepatol 2008;48(Suppl 2):S370-1
   Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis c virus infection: results of a prospective randomised trial. J Hepatol 2008;48(Suppl 2):S370
   Google Scholar
• Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-60
   PubMed Web of Science ®Google Scholar
• Powis J, Peltekian KM, Lee SS, et al. Exploring differences in response to treatment with peginterferon alpha 2a (40 kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008;15:52-7
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-77
   PubMed Web of Science ®Google Scholar
• Ferenci P. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol Dietol 2006;52:157-74
   PubMedGoogle Scholar
• Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103
   PubMed Web of Science ®Google Scholar
• Nyberg LM, Shiffman M, Bonilla H, et al. Predicting the ability to achieve a sustained virologic response (SVR) in the first 12 weeks: Results from the IDEAL study. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco, USA. October 31 – November 4
   Google Scholar
• Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42
   PubMed Web of Science ®Google Scholar
• von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-27
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73-81
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34
   PubMed Web of Science ®Google Scholar
• Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004;189:964-70
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97
   PubMed Web of Science ®Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44
   PubMed Web of Science ®Google Scholar
• Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997;17:530-48
   PubMed Web of Science ®Google Scholar
• Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004;2:337-39
   PubMed Web of Science ®Google Scholar
• Rebetron (combination therapy containing Rebetol [ribavirin, USP] capsules and Intron A [interferon alfa-2b, recombinant injection]) prescribing information. Kenilworth, NJ. Schering, January 2001
   Google Scholar
• Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11
   PubMed Web of Science ®Google Scholar
• Cooper CL, Al-Bedwawi S, Lee C, et al. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-78
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998;28:1424-29
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36
   PubMed Web of Science ®Google Scholar
• Horsmans Y. Interferon-induced depression in chronic hepatitis C. J Antimicrob Chemother 2006;58:711-13
   PubMed Web of Science ®Google Scholar
• Singh N, Gayowski T, Wagener MM, et al. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 1997;11:406-11
   PubMed Web of Science ®Google Scholar
• Ferenci P, Staufer K. Depression in chronic hepatitis: the virus, the drug, or the ethnic background? Liver Int 2008;28:429-31
   PubMed Web of Science ®Google Scholar
• Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004;18:41-6
   PubMed Web of Science ®Google Scholar
• Rothfuss KS, Bode JC. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C. Z Gastroenterol 2002;40:807-10
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol 2007;34:577-82
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A, Shiffman ML, Everson GT, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2007;46(Suppl 1):290A
   Google Scholar
• Poynard T, Schiff E, Terg R, et al. Sustained virologic response (SVR) in the EPIC3 trial: week 12 virology predicts SVR in previous interferon/ribavirin treatment failures receiving Peg-Intron/Rebetol weight based dosing. J Hepatol 2005;42(Suppl 2):40
   Google Scholar
• Jensen DM, Freilich B, Andreones P, et al. Pegylated interferon alfa-2a (40 KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12 KD)/RBV: final efficacy and safety outcomes of the REPEAT study. Hepatology 2007;46(4 Suppl):80A
   Google Scholar
• Afdahl N, Levine R, Brown R, et al. Colchicine versus Peg-Interferon Alfa 2b Long Term Therapy: Results of the 4 year COPILOT Trial. 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008). Milan, Italy. April 23 – 27
   Google Scholar
• Gross J, Johnson S, Kwo P, et al. Double-dose peginterferon alfa-2B with weight-based ribavirin improves response for interferon? ribavirin non-responders with hepatitis C: final results of ‘RENEW’. Hepatology 2005;42(Suppl 1):219A
   Google Scholar
• Bergmann JF, Vrolijk JM, van der Schaar P, et al. γ-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-a-2b in chronic hepatitis C non-responders. Liver Int 2007;27:1217-25
   PubMed Web of Science ®Google Scholar
• Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004;39:1213-19
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-57
   PubMed Web of Science ®Google Scholar
• Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006;43:250-56
   PubMed Web of Science ®Google Scholar
• Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004;39:1721-31
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8
   PubMed Web of Science ®Google Scholar
• Angerami RN, Goncales Junior FL. Therapeutic approach to acute hepatitis C. Braz J Infect Dis 2007;11:535-39
   PubMed Web of Science ®Google Scholar
• Kaplan M, Gawrieh S, Cotler SJ, et al. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology 2003;125:597-604
   PubMed Web of Science ®Google Scholar
• Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-38
   PubMed Web of Science ®Google Scholar
• Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006;43:54-9
   Google Scholar
• Pineda JA, García-García JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007;46:622-30
   PubMed Web of Science ®Google Scholar
• Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000;157:867-76
   PubMed Web of Science ®Google Scholar
• Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-82
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-59
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-48
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing PEG-interferon-2b vs PEG-interferon-2a, both plus ribavirin, to treat chronic hepatitis C in HIV patients. Hepatology 2009;49:22-31
   Google Scholar
• Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-8
   PubMed Web of Science ®Google Scholar
• Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, et al. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Antivir Ther 2007;12:523-29
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1802-03
   PubMedGoogle Scholar
• Pineda JA, Mira JA, Gil IL, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007;60:1347-54
   PubMed Web of Science ®Google Scholar
• Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008;47:94-101
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Dieterich DT, Bini EJ, et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005;39:504-6
   PubMed Web of Science ®Google Scholar
• Mira J, López-cortes L, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus-coinfected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; In press
   Google Scholar
• Vispo E, Barreiro P, Pineda J, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13:429-37
   PubMedGoogle Scholar
• Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540-48
   PubMed Web of Science ®Google Scholar
• Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-78
   PubMed Web of Science ®Google Scholar
• Bain VG, Kaita KD, Marotta P, et al. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:701-06
   PubMed Web of Science ®Google Scholar
• Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001;61:1661-91
   PubMed Web of Science ®Google Scholar
• Aladag M, Karasu Z, Wright H, et al. Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: one year follow-up after 48 weeks of treatment. Turk J Gastroenterol 2006;17:35-9
   PubMedGoogle Scholar
• Witthoeft T, Fuchs M, Ludwig D. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. World J Gastroenterol 2007;13:579-84
   PubMed Web of Science ®Google Scholar
• Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007;59:1222-41
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Jeffers L, Afdhal N, et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007;45:569-78
   PubMed Web of Science ®Google Scholar
• Soza A, Heller T, Ghany M, et al. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol 2005;43:67-71
   PubMed Web of Science ®Google Scholar
• Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006;57:8-13
   PubMed Web of Science ®Google Scholar
• Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008;15:2-11
   PubMed Web of Science ®Google Scholar
• Lang L. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C. Gastroenterology 2007;132:2283-4
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor SCH 503034, plus peg-Intron in hepatitis C genotype-1 peg-Intron nonresponders: phase 1 b results. Hepatology 2005;42(Suppl 1):276A
   Web of Science ®Google Scholar
• Mchutchison JG, Everson GT, Gordon SC, et al. PROVE 1: Results from a Phase 2 study of telaprevir with peginterferon alpha-2a and ribavirin in treatment-naive subjects with hepatitis C. J Hepatol 2008;48(Suppl 2):S4
   Web of Science ®Google Scholar
• Shiffman M, Berg T, Poordad F, et al. A study of telaprevir combined with petinterferon-alfa 2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa 2a and ribavirin treatment: Interim analysis. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, USA. October 31 – November 4, 2008
   Google Scholar
• Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-9
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8
   PubMed Web of Science ®Google Scholar
• Kwo P, Lawitz E, McCone E, et al. Interim results from HCV SPRINT-1: RVR/EVR from Phase 2 study of boceprevir plus pegintron™ (peginterferon alfa-2B)/ribavirin in treatment-naive subjects with genotype-1 CHC. J Hepatol 2008;48(Suppl 2):S372
   Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 2008;27:866-84
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008;48:385-97
   PubMed Web of Science ®Google Scholar
• McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-12
   PubMed Web of Science ®Google Scholar
• Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs 2007;8:125-9
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98
   PubMed Web of Science ®Google Scholar
• Keck ZY, Machida K, Lai MM, et al. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 2008;317:1-38
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in chronic hepatitis C genotype 4 patients given nitazoxanide, peginterferon and ribavirin. Gastroenterology 2008; In press
   PubMedGoogle Scholar
• Lai L, Hui CK, Leung N, et al. Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine 2006;1:255-62
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43:S207-20
   PubMed Web of Science ®Google Scholar